Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 8th Preview)
-
Big pharma ophthalmology M&A
Bayer struck a deal to expand its ophthalmology pipeline by acquiring Perfuse Therapeutics for up to $2.45 billion. The purchase gives Bayer full rights to PER-001, a small-molecule endothelin receptor antagonist being developed for glaucoma and diabetic retinopathy via a bioerodible intravitreal implant. Perfuse’s Phase II programs showed clinical activity after a single intravitreal administration, with improvements in ocular blood flow and visual function outcomes reported across multiple endpoints for glaucoma and diabetic retinopathy. Bayer also pointed to its existing ophthalmology footprint, including Eylea commercialization supported by Regeneron, as it looks to deepen its eye franchise beyond VEGF. The transaction includes a $300 million upfront payment plus development, regulatory, and commercial milestones, positioning PER-001 as a potential disease-modifying addition in areas where no drugs in this endothelin class are currently approved for eye disorders.
-
FDA reconsideration for cell therapy
Pierre Fabre and Atara Biotherapeutics won a significant pivot from the U.S. FDA on Ebvallo (tabelecleucel) after the agency’s earlier surprise rejection. The FDA agreed to reconsider approval support using a single-arm study paired with an appropriate historical control framework, according to company statements. The therapy is aimed at patients with relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (EBV+PTLD) after failure of an anti-CD20 regimen. The earlier FDA decision in January cited the same single-arm trial as not adequate and well-controlled due to multiple deficiencies, but the latest discussion establishes a resubmission pathway without initiating a new separate trial. Pierre Fabre’s CEO for its U.S. subsidiary said the companies will finalize a resubmission plan with additional patients and longer follow-up under the agreed framework, following earlier progress in Europe where the immunotherapy received approval in 2022.
-
Digital pathology consolidation
Roche agreed to acquire PathAI in a deal potentially worth up to $1.05 billion, aiming to accelerate the rollout of AI-powered diagnostic tools within Roche Diagnostics. The acquisition includes a $750 million upfront payment and additional milestone payments of up to $300 million, and is expected to close in the second half of 2026 subject to regulatory approvals. Roche will fold PathAI into its Diagnostics division to scale PathAI’s Image Management System and workflow capabilities globally. The companies also cited their prior collaboration, including work on AI-enabled companion diagnostic algorithms, with PathAI’s platform supporting clinical trial analytics and translational research workflows. The move aligns with a broader push to industrialize digital pathology as an operational layer for precision oncology, potentially enabling faster biomarker development and more scalable diagnostic decision support across pharma partners.
-
Precision oncology startup funding
Imagenomix, an NYU Langone spinout developing AI-driven cancer diagnostics from standard histopathology images, raised $3.2 million in seed funding. The company said it uses AI to detect genetic alterations directly from tissue slides and map spatial mutation distribution without requiring sequencing. Imagenomix plans to use the financing to initiate a clinic trial in breast cancer and to commercialize a V2 lung cancer classifier later in 2026 in collaboration with digital pathology firm Proscia. The company also intends to support its alliance with Alterome Therapeutics, where its platform is being used in Phase I studies for precision oncology candidates. The seed round was led by Modi Ventures with participation from NYU Langone Venture Fund and other named venture vehicles, highlighting continued investment in image-to-genomics approaches for molecular-grade decision support.
-
Biotech IPO market: autoimmunity
Odyssey Therapeutics priced and launched its initial public offering, raising $279 million at $18 per share, plus an additional $25 million from a concurrent private stock sale at the same price. The company’s IPO follows a prior delay more than a year earlier and positions Odyssey to begin Nasdaq trading under the ticker ODTX. Odyssey’s proceeds come amid investor demand for larger biotech offerings, with the company highlighting a venture-backed funding base that totals $727 million. The IPO marks another addition to the year’s slate of drug company debuts after an extended period in which biotech listings slowed relative to prior years. The move is significant for the autoimmune pipeline segment, where Odyssey is aiming to translate clinical progress into public-market scale with access to additional capital for development.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.